Abstract: Objective To evalulate the objective response rate, progression-free survival（PFS）and toxicity of Docetaxe or Oxaliplatin combined with Xeloda for advanced gastric cancer. Methods Forty-one patients with advanced gastric cancer were randomized and divided into two groups. Group A consisted of 19 patients received Docetaxe plus Xeloda and group B with 22 patients received Oxaliplatin plus Xeloda. The treatment was repeated every 3 weeks until disease progression or limiting toxicities. Two or more cycles chemotherapy were completed for all of patients. Results Forty-one patients were assessable for efficacy and toxicities. In group A and B,the response rate (CR+PR) was 52.63% and 54.55 %,respectively. The median progression-free survival in group A was similar to that in group B (6.1 months vs. 6.3 months, Log Rank=1.99， P=0.1588）. The most common adverse effects were myelosuppression and gastrointestinal response in each group. Myelosuppression in group A was moderately frequent compared with that in group B . On the contrary, the rate of mild neurotoxicity in group B was a little increased. No chemotherapy-related death was observed. Conclusion The effects of docetaxe or Oxaliplatin combined with Xeloda for advanced gastric cancer were comparable and appropriate with a well tolerance.